NICE has recommended routine NHS access to nusinersen and risdiplam for spinal muscular atrophy, ending time-limited managed access schemes in place since 2019.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/two-sma-drugs-move-routine-nhs-funding-2026a1000fnk?src=rss
Author :
Publish date : 2026-05-14 13:32:00
Copyright for syndicated content belongs to the linked Source.